Post Profile






Not So Wondrous Drugs? - New Warnings about Severe Adverse Effects of New, Heavily Marketed Drugs for Hepatits C,

Background - Wonder Drugs for Hepatitis C In our April, 2014, post we noted how Sovaldi (sofosbuvir), the new antiviral drug made by Gilead for hepatitis C was touted as a "triumph of of medical technology." In that, and subsequent posts we discussed how such claims were not buttressed by much good data from clinical research.We could find only one published randomized clinical trial of sofosbuvir (and ribavirin), which compared it to the older drug used to treat hepatitis C, peg-interferon (and ribavirin).
read more

share

Related Posts


Sovaldi: The drug pricing paradigm has shifted

Industries / Medical : Kevin MD Medical Weblog

Sovaldi (sofosbuvir), the new hepatitis drug manufactured and marketed by Gilead Sciences, has garnered considerable media attention over the last several months. The drug was approved by the FDA in December after phase III clinical...

Knee Deep in the Hoopla - "A Triumph of Medical Technology" Sans Evidence of Superiority from Published Randomized Double Blind Controlled Trials

Industries / Medical : Health Care Renewal

With the publication of several new articles in the prestigious New England Journal of Medicine, the buzz about Sovaldi (sofosbuvir - Gilead), a new oral treatment of hepatitis C, has become feverish. The drug had been hailed as nea...

Some Authoritative Skepticism about the "Triumph" of Sovaldi to Add to Outrage about "Blood Money"

Industries / Medical : Health Care Renewal

Three weeks ago we posted about the continuing controversy over the stratospheric price of the new antiviral drug for hepatitis C (HCV), sofosbuvir (Sovaldi, by Gilead). While the amazing $1000 per pill price got deserved attention,...

Sovaldi - a "Revolution" in Clinical Care, or in Marketing and Public Relations?

Industries / Medical : Health Care Renewal

The continuing public discussion of the sky high price Gilead has set for Sovaldi (sofosbuvir,) its new antiviral drug for hepatitis C, continues to avoid considering the lack of good evidence that the drug is as safe and effective ...

As the Hepatitis C Marketing Frenzy Continues, a Reminder Not to Ignore the Evidence

Industries / Medical : Health Care Renewal

The Hepatitis C Spin Cycle Continues Since our last post in July, 2014, about sofosbuvir (Sovaldi, Gilead), the $1000 pill proclaimed to be a wonder drug for the treatment of hepatitis C, the marketing juggernaut for new antiviral d...

Comments


Copyright © 2016 Regator, LLC